From the Department of Pediatrics, Gazi University, Ankara, Turkey.
Exp Clin Transplant. 2022 May;20(Suppl 3):129-136. doi: 10.6002/ect.PediatricSymp2022.O41.
Neutrophil-to-lymphocyte ratio and platelet (thrombocyte)-to-lymphocyte ratio have become accepted markers of inflammation in recent years and are used to assess disease activity in some diseases. In this study, we investigated the relationship between these values and acute rejection attacks, as well as their role in determining chronic allograft nephropathy, in follow-up of pediatric kidney transplant recipients.
Our study included 58 kidney transplant recipients (age 5-18 years) with at least 5-year follow-up at our center. Patients with history of secondary transplant, concomitant malignancy, and shorter follow-up were excluded. Medical history and laboratory parameters pretransplant and at 1, 3, and 6 months and 1, 2, 3, 4, and 5 years posttransplant, as well as kidney biopsy reports, were reviewed.
Both neutrophil-to-lymphocyte (P = .003) and thrombocyte-to-lymphocyte (P = .002) ratios were significantly higher during acute rejection attacks. Although both values were higher in patients with chronic allograft nephropathy at 5 years posttransplant, differences were not statistically significant (P = .69 and P = .55). When patients with and without chronic allograft nephropathy within 5 years were compared, those who developed chronic allograft nephropathy had significantly higher neutrophil- tolymphocyte and thrombocyte-to-lymphocyte ratios at all periods in the first 2 and 4 years posttransplant, respectively. Among patients who had acute rejection attacks, those who subsequently developed chronic allograft nephropathy had higher neutrophil-tolymphocyte ratio in the first 3 years posttransplant, with higher thrombocyte-to-lymphocyte ratio at all posttransplant periods.
This is the first study on neutrophil- tolymphocyte and thrombocyte-to-lymphocyte ratios in pediatric kidney transplant recipients. Our results indicated that both values can be useful and easily accessible markers in acute rejection diagnosis and determining chronic allograft nephropathy development risk, which are 2 major causes of kidney graft loss posttransplant. Pediatric studies with larger populations are needed to support our findings.
中性粒细胞与淋巴细胞比值和血小板(血栓形成细胞)与淋巴细胞比值近年来已被视为炎症标志物,并用于评估某些疾病的疾病活动度。本研究旨在探讨这些值与急性排斥反应之间的关系,并在我们中心接受肾移植的儿科患者随访中评估其在确定慢性移植肾肾病中的作用。
我们的研究纳入了 58 例至少在我们中心接受 5 年随访的肾移植受者(年龄 5-18 岁)。排除了有二次移植史、合并恶性肿瘤和随访时间较短的患者。回顾了患者的病史和实验室参数,包括移植前、移植后 1、3 和 6 个月以及 1、2、3、4 和 5 年的参数,以及肾活检报告。
在急性排斥反应发作期间,中性粒细胞与淋巴细胞比值(P =.003)和血小板与淋巴细胞比值(P =.002)均显著升高。尽管在移植后 5 年时慢性移植肾肾病患者的这两个值均较高,但差异无统计学意义(P =.69 和 P =.55)。比较移植后 5 年内有或无慢性移植肾肾病的患者,发生慢性移植肾肾病的患者在移植后 2 年和 4 年的所有时间点,中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值均显著更高。在发生急性排斥反应的患者中,随后发生慢性移植肾肾病的患者在移植后 3 年内中性粒细胞与淋巴细胞比值更高,而在所有移植后时期血小板与淋巴细胞比值更高。
这是第一项关于儿科肾移植受者中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的研究。我们的研究结果表明,这两个值都可以作为急性排斥反应诊断和确定慢性移植肾肾病发展风险的有用且易于获取的标志物,而这两个因素是移植后导致肾移植物丢失的两个主要原因。需要进行更大人群的儿科研究来支持我们的发现。